CEMIPLIMAB clinical trials

Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC)

This study, called ICONIC, is looking at how a combination of powerful cancer medications and a special type of radiation therapy called carbon ion radiotherapy works for certain solid cancers that haven't responded to other treatments. We want to see if this combination can shrink tumours and improve patients' health.

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

This study is testing a new drug, ubamatamab, alone or with cemiplimab, for recurrent ovarian or endometrial cancer. It aims to see how safe it is, how it works in the body, and if it can help treat these cancers.

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

This study is comparing two drug combinations for advanced melanoma skin cancer: fianlimab plus cemiplimab, and pembrolizumab. It aims to see which is more effective, what side effects occur, and how they affect adults and teenagers.

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

This study looks at a new drug, cemiplimab, for people who have had surgery and radiotherapy for a serious form of skin cancer (squamous cell carcinoma). We want to see if cemiplimab can stop the cancer from coming back.

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

This study is looking at new combinations of immunotherapy drugs for people with advanced lung cancer. It combines an existing drug, Cemiplimab, with one of three new drugs (S095018, S095024, or S095029) to see which combination is safe and works best.

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

This study looks at new drug combinations (fianlimab with cemiplimab) versus a standard drug (pembrolizumab) to see if they can stop melanoma from coming back after surgery. It's for people at high risk of their melanoma returning.

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

This study looks at a new drug, BNT116, for advanced lung cancer. It explores if BNT116 is safe, how much to give, and how well it works when used alone or with other treatments for different types of non-small cell lung cancer.

ETCABio - Evaluation of Skin Tests in Biotherapy Allergies

This study looks at how your skin reacts to certain advanced cancer medicines, called biotherapies. We're finding the strongest dose that doesn't cause a skin reaction in most people when tested on the skin, to make these treatments safer.

MOIO_Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with locally advanced or metastatic cancer in response after 6 months of standard IO